T hroughout medical school, I heard one attending physician after another bemoan the death of the physical examination. "I can read the echo report myself," a cardiologist once chided me when I detailed the specifics of a patient's tricuspid regurgitation-jet velocity, "but right now I'd like to know what you heard with your stethoscope." On another occasion, I spent a grueling half hour by the bedside, struggling to answer endless questions from a rheumatologist about a patient's fingernails. During a month with the endocrinology team, I was assigned to simulate hypocalcemia, faking facial twitches and carpal spasms, as my fellow medical students tapped at my cheeks and checked my blood pressure. The point of these exercises was to ensure that I, a 21st-century medical student with hundreds of imaging studies and thousands of laboratory assays at my disposal, would not forget that the best doctors help their patients with their eyes, ears, and hands, not just with numbers posted on a computer screen.
As a new resident in internal medicine, I would like to say that I have emulated these doctors, but unfortunately, the opposite has been true. Each day on the wards, I see a dozen or so patients, and my physical exams have been condensed to roughly 60 seconds: a quick look at the eyes, a quicker look into the mouth, gross palpation of the neck, a cursory listen to the heart and lungs, a squeeze of the belly, another squeeze of both legs, and a touch of the hands and feet to make sure they're still warm. In contrast, I spend hours each day checking laboratory values on the computer, ordering and reviewing studies, and following up on the results of various diagnostic procedures.
Still, I have come to appreciate one part of the physical exam that cannot be replaced by blood draws and x-rays, a part in which I have actually improved since first donning a long white coat. This part often doesn't make it into my official histories or daily progress notes, but its prognostic implications can be as important as those of the white-cell count or costophrenic angles. I am referring to a patient's smell.
In a closed hospital room, odors are often much easier to appreciate than carotid bruits. I have been greeted by enough stenches on removing dressings from the feet of diabetic patients to know whether someone is going to need intravenous or oral antibiotics. I have sniffed sufficient foul-scented tracheostomy sites that I'm no longer surprised when sputum cultures grow out a mixture of oral flora. I have done morning rounds for so many patients who are being prepped for colonoscopy that I now know who has and who has not received a full dose of GoLytely. When a nephrologist asked whether my new patient's confusion was due to her age or her renal function, I felt confident choosing uremia on the basis of her fetid breath.
Smells also indicate in which direction a patient is headed. A patient who has showered and brushed his teeth before 6:30 a.m. is obviously getting ready to go home, no matter what his laboratory values might say. More than once, just a few sniffs have let me know that I can advance a patient's diet without embarrassing her by asking whether she's been passing gas. When I admit a new patient from the emergency room who reeks of cigarette smoke, I make a mental note to watch his oxygen requirements closely and to keep cancer in my differential diagnosis no matter what the reason for his presentation.
But the case of the man I'll call Gordon Watson perhaps taught me the most of all. Mr. Watson's odor was one that I'd never smelled before and one that I hope, for the sake of my future patients, I never smell again. Mr. Watson was a 50-year-old man with diabetic and hypertensive nephropathy who had been receiving hemodialysis for 10 years. He was transferred to our hospital for treatment of what was believed to be antibiotic-resistant bullous cellulitis of the left thigh. Once he arrived, surgeons excised and débrided this supposed wound, whose culture turned out to be consistent with calciphylaxis -a systemic calcification of the cutaneous blood vessels that leads to profound tissue ischemia. This rare complication of renal failure is a devastating disease associated with mortality rates as high as 60 to 80 percent.
When Mr. Watson was transferred to my service, I was not surprised to learn from the resident who had signed him out of the ICU that he had been treated with pressors and continuous venovenous hemofiltration in addition to broad-spectrum antibiotics; like many patients with calciphylaxis, he had had sepsis from infected, necrotic skin lesions. I was taken aback, however, when I first entered Mr. Watson's room. Although the medical literature had provided plenty of information on the pathogenesis, clinical manifestations, and potential avenues of treatment for calciphylaxis, I hadn't come across a single word about the syndrome's smell. "That's the stench of death," Mr. Watson's nurse informed me when she saw me trying to recapture my breath as I left his room. "I knew right away he was a calciphylaxis patient, because I've only smelled that smell once before. I'm going to put a peppermint aerosol in his room, but I doubt it will help." Since Mr. Watson was the sickest patient on my service, I saw him four to five times a day. I soon discovered the single spot in his room that smelled like peppermint, and I stayed rooted in that one-squarefoot area beside his IV pole while I asked him questions and listened to his answers. When we finished talking, I held my breath and condensed my 1-minute physical exam into 15 seconds of listening to the heart, lungs, and abdomen by planting the bell of my stethoscope in the "intern's spot," the magical area on a patient's chest where breath, heart, and bowel sounds can all be heard. Then I left the room and breathed in the relatively fresh air of the hospital hallway.
Over the next week, the peppermint spot shrank to a few square inches, and Mr. Watson's answers became less and less coherent. The same disease that had killed the blood vessels leading to his skin and brain had clotted off the dialysis catheter in his right thigh, which had been the last place a catheter could be inserted. My attending met with Mrs. Watson to discuss transitioning her husband's care to comfort measures only. I stood outside the closed door of his room, watching through a small window as he squirmed in distress, and I could still smell him. The odor had drifted out under the door, I surmised. That afternoon, I started a morphine drip for Mr. Watson and let the coverage team know that he might die overnight. He didn't.
Meanwhile, his smell had somehow made its way into my apartment, into my bathroom when I showered, into my kitchen as I made dinner, into my living room and bedroom. His smell was in my car the next morning as I drove to the hospital. I smelled his dying skin on all my patients, on all the new patients I admitted, and I didn't stop smelling Mr. Watson until three in the morning the following day, when I was paged out of my bed in the call room to declare him dead.
In the following days, I couldn't shake the knowledge that the longest physical exam I'd performed on Mr. Watson was the one that I'd done that morning, after he'd died. It was also, regrettably, the longest period of uninterrupted time I'd spent by his side. I had spent hours sifting through his chart trying to understand his lengthy hospital course. I had repeatedly checked his laboratory values to ensure that my choice of antibiotics was appropriate and to gauge the levels of toxins in his body. But once it became clear that Mr. Watson was going to die, it was his smell and not his serum creatinine level that came home with me. In essence, he had ceased being my patient and had simply become a person approaching his final hours, and all I really knew of this man was his odor.
After he passed away, Mr. Watson's smell no longer haunted me, but I was left with the unsettling feeling that I had not fully done my job as his physician. That job involves not just taking care of a patient, but also caring about a person. Today, I can't remember Mr. Watson's last calcium-phosphorus product or whether the Staphylococcus aureus that grew out of his wound culture was sensitive to oxacillin, but I can recall exactly how he smelled. I now know that the attending physicians who preached the gospel of the physical exam were not merely trying to help me hone my diagnostic skills. They were also stressing the need to spend as much time with patients as with tests.
Since I became a resident, my understanding of iron panels, pulmonary-function tests, hepatitis serologic profiles, and cardiaccatheterization reports has vastly improved, and this undoubtedly makes me a more competent physician. But I didn't enter medi- cine with the goal of simply becoming competent. I want to be the kind of doctor whom a patient can trust, the kind who listens and touches and takes the time to look at a patient to see how he or she is truly faring. For now, I can count my improved sense of smell as a small victory in that quest.
(Identifying details about the patient have been changed to protect his privacy.) Dr. Bomback is a resident in internal medicine, University of North Carolina Hospitals, Chapel Hill.
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Related article, page 353 I t is a cornerstone of medical practice to "first, do no harm." Yet the body of evidence that is sufficient to demonstrate efficacy for a new drug is rarely large enough to provide absolute assurance that harmful side effects do not exist. Thus, ongoing surveillance is necessary to detect adverse events.
There are many reasons why the randomized trials that are adequate for demonstrating drug efficacy may not be adequate for the recognition of important side effects (see table) . Randomized trials may be too small to permit the detection of adverse events. For instance, for a continuous outcome such as blood pressure or the change in a pain scale, in a trial with a before-and-after or crossover design, even a few dozen patients may be an adequate number to demonstrate an effect. Trials are often conducted over weeks or a few months, obviating any possibility of detecting longerlatency effects that require exposure for many months or years. Finally, trials may be conducted in a population from which patients with coexisting illnesses have been excluded and thus do not address the question of whether the drug may do harm once approved and prescribed to these patients.
The detection of adverse events also depends on the background incidence of these conditions. The occurrence of two cases of progressive multifocal leukoencephalopathy among 3000 patients treated with natalizumab (Tysabri) in clinical trials was enough to cause the drug to be withheld from the market. Less remarkable conditions, such as heart attacks associated with the use of cyclooxygenase-2 (COX-2) inhibitors, are less likely to raise flags. To detect an increase in the incidence of these conditions requires careful statistical analyses of unblinded data and adequate study power. In this paradoxical manner, we may be better protected from exposure to drugs that cause very rare medical conditions than from exposure to those that cause common, unremarkable conditions.
Once concern has been expressed about a drug and specific adverse events, it is often proposed that the Food and Drug Administration mandate that companies conduct clinical trials to prove whether the drug does or does not cause the events. This approach is always preferred, but such studies may have to be almost unfeasibly large, and for drugs shown to be efficacious in the treatment of serious conditions, it may be argued that it is unethical to conduct a placebo-controlled trial to search for adverse events (see table) . In Trials powered for efficacy may be too small to detect adverse events.
Monitoring of adverse events may not be sensitive or specific for the actual events caused.
Duration of trials may be too short for detection of events requiring longer exposure.
Stopping rules in clinical trials may further shorten the duration of exposure after randomization.
Enrollment criteria may exclude susceptible subgroups.
For industry-sponsored trials, head-to-head comparison of adverse events due to drugs from different manufacturers may not be available.
